Key facts
- It has raised $18.1M across 4 recorded rounds; the latest was Early Stage VC ($12.8M) in Mar 2024.
- Notable investors include Pennsylvania Department of Community and Economic Development, Alexandria LaunchLabs, Dreavent, Monfort.
- Chimeron Bio has filed 5 Form Ds with the SEC since 2020, most recently Mar 2025 ($12.8M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Chimeron Bio
Funding rounds
4 roundsAbout Chimeron Bio
Developer of self-amplifying therapeutics and vaccines intended to offer gene therapies and personalized medicines to patients. The company's platform leverages chimera-encased self-amplifying RNA to achieve superior expression and a broader dynamic range compared to other leading messenger RNA technologies, enabling physicians to treat patients with serious diseases including cancer, infectious diseases, and genetic disorders.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2015
- Employees
- 14
- Website
- chimeron.com/
- Ownership
- Privately Held (backing)
Chimeron Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chimeron Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chimeron Bio in its N-PORT filings yet. We sweep new filings monthly.